Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02931539 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 352
- Enrollment target
NCT02931539 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 352 participants.
The verdict
NCT02931539, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 352 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV treatment.
Interventions
- DRUG Valganciclovir
- DRUG Maribavir
- DRUG Cidofovir
- DRUG Ganciclovir
- DRUG Foscarnet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2020-08-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02931539
The ClinicalTrials.gov registry entry for NCT02931539 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 352 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Valganciclovir is the first listed.
NCT02931539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02931539 about?
NCT02931539 is a clinical study titled "Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir". The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV treatment.
What is the current status of trial NCT02931539?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 352 participants. The study started on 2016-12-22. Estimated completion is 2020-08-17.
What interventions are being tested in trial NCT02931539?
The interventions under investigation include: Valganciclovir (DRUG), Maribavir (DRUG), Cidofovir (DRUG), Ganciclovir (DRUG), Foscarnet (DRUG).
Who is sponsoring clinical trial NCT02931539?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.